DNA damage response as biomarkers informing a precision medicine approach to bladder cancer: what are the next steps?

Scot Niglio, Matthew D. Galsky

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)7-9
Number of pages3
JournalExpert Review of Precision Medicine and Drug Development
Issue number1
StatePublished - 2 Jan 2019


  • Bladder cancer
  • CTLA4
  • DDR
  • DNA damage response
  • ERCC2
  • PD-1
  • PD-L1
  • check point blockade
  • cytotoxic T-lymphocyte-associated protein 4
  • program cell death ligand 1
  • urothelial cancer

Cite this